Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475605 · ClinicalTrials.gov registry record
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
A clinical trial, sponsored by LEO Pharma.
- Terminated
- Registry status
- 8,071
- Enrollment target
NCT00475605 is a clinical trial that was terminated before completion, run by LEO Pharma. The registered enrollment target is 8,071 participants.
The verdict
NCT00475605 was terminated before completion, sponsored by LEO Pharma.
- TERMINATED
- Registry status
- 8,071 participants
- Enrollment target
Study Summary
This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were \< 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,071 participants |
| Start Date | 2005-05-25 |
| Est. Completion | 2019-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475605
The ClinicalTrials.gov registry entry for NCT00475605 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8,071 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00475605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00475605 about?
NCT00475605 is a clinical study titled "A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis". This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were \< 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.
What is the current status of trial NCT00475605?
This trial is currently terminated. The enrollment target is 8,071 participants. The study started on 2005-05-25. Estimated completion is 2019-01-31.
Who is sponsoring clinical trial NCT00475605?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.